Why Emocog
We create technology that helps sustain brain health
Dementia affects about 10% of the senior population and progresses over a decade. The stage of memory decline before dementia is called Mild Cognitive Impairment (MCI) and progresses overhalf a decade. The prevalence rate is about 25%.
Emocog develops solutions for each stage of dementia, including Cogthera, a cognitive improving digital therapeutics for MCI.
Research
Technology based on world-class scientific results
The results of 20 years of research was published in 5 leading *SCI-indexed journals on brain disease.
*Science Citation Index (SCI): renowned journals carefully selected based on strict criteria among science and technology journals
Solution 1
Emocog builds an ecosystem to care for the entire journey from screening, diagnosis and treatment of dementia.
To overcome the physical constraints of not being able to care for every patient every day, we propose innovative solutions utilizing digital technology.
*Digital treatments and medical applications(DiGA) are virtual medical products that are available as apps for mobile devices or as browser applications. Cogthera DE can quickly enter the market and receive very high insurance rates through these process.
Emocog’s Digital Dementia Solutions
LAUNCH
DATA COLLECTION
& ANALYSIS
DETAILED
DESIGN
PROTOTYPE
& TEST
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
MemoryPick Mobile Cognitive Assessment Service to Screen for Dementia Risk
LAUNCH
PRODUCT
APPROVAL
CLINICAL
EVALUATION
PERFORMANCE
TEST
DETAILED
DESIGN
PROTOTYPE
& TEST
PROOF OF
CONCEPT
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
Cogthera KR Digital Therapeutics for MCI
LAUNCH
PRODUCT
APPROVAL
CLINICAL
EVALUATION
DEVELOPMENT
& PROGRAMING
CONCEPTION
REQUIREMENT
ANALYSIS
(DiGA* fast track process in Germany)
Cogthera DE German-optimized Digital Therapeutics for MCI
LAUNCH
DATA COLLECTION
& ANALYSIS
DETAILED
DESIGN
PROTOTYPE
& TEST
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
PDT Parkinson’s Disease Diagnostic Assistant Software
LAUNCH
DATA COLLECTION
& ANALYSIS
DETAILED
DESIGN
PROTOTYPE
& TEST
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
AlzVoice Memory and Attention Assessment Service based on Verbal Conversation
It is a responsive web-based online test that can be performed on various devices and operating systems through a QR or a URL.
The test takes only about 5 minutes, providing comfortable and easy-to-use content based on simple words and shapes.
Improve the accuracy of the results through large-scale compliance data by accounting for differences in cognitive function based on age, education, gender, etc.
MemoryPick
MemoryPick is a digital screening tool that helps users detect early signs of cognitive decline. It evaluates memory and executive function, which are the first cognitive areas to decline due to dementia, as well as subjective cognitive decline and depression.
At the end of the test, it shows an instant results report representing the user’s brain health. Based on the results, it recommends memory strategies to help daily life and lifestyle habits to keep the brain healthy.
Mobile cognitive assessment service to help screen for dementia risk
1
Conversation-based interface using vocal cues, made for the convenience of patients with early cognitive decline.
After accurate assessments of the patient’s cognitive ability, training contents are automatically generated via AI technology, providing personalized training with difficulty adjustments.
Accessible anytime and anywhere, free from restraints of professional presence, location, and time.
Cogthera
Cogthera constantly monitors patients’ cognitive functions and provides personalized cognitive training to strengthen the neural networks and increase the *cognitive reserve.
It was designated as an Innovative Medical Device by MFDS and became the first cognitive intervention treatment software for MCI to be designated as an Innovative Medical Device in Korea.
Software as a Medical Device to improve Mild Cognitive Impairment
2
In addition to clinical trials in Korea, Cogthera is simultaneously pursuing German DiGA (Digital treatment and medical applications). DiGA is a fast-track system by German regulatory, BfArM, with an advantage of fast market entry and high reimbursement rate.
DiGA Fast Track
Solution 2
Digital Solutions for Learning Disorder
With Happymind, the developer of CAT, which has a high market share in Korea, we are rapidly growing by sharing development technology, know-how, and networks accumulated over the years.
Happymind evaluates problems related to learning disorders such as attention deficit, poor reading skills and poor math skills, and provides solutions to them.
LAUNCH
DATA COLLECTION
& ANALYSIS
DETAILED
DESIGN
PROTOTYPE
& TEST
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
CAT Comprehensive Attention Test for children and adults
LAUNCH
DATA COLLECTION
& ANALYSIS
DETAILED
DESIGN
PROTOTYPE
& TEST
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
NeuLearn Application using neuroscience-based learning techniques to help memorize English words
LAUNCH
DATA COLLECTION
& ANALYSIS
DETAILED
DESIGN
PROTOTYPE
& TEST
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
Dyscalculia Treatment Program Program to treat those with mathematical and calculational difficulties
LAUNCH
DATA COLLECTION
& ANALYSIS
DETAILED
DESIGN
PROTOTYPE
& TEST
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
sCAT Short version of CAT for institutions
LAUNCH
DATA COLLECTION
& ANALYSIS
DETAILED
DESIGN
PROTOTYPE
& TEST
CONCEPT
DEVELOPMENT
DEFINE
THE BRIEF
CLT Comprehensive Learning Test for early screening of dyslexia and dyscalculia in children and adolescents
Completed a standardized study of 4-49 years olds, providing more objective results
The only attention test certified by the Korean Academy of Child and Adolescent Psychiatry
CAT
Happymind’s CAT (Comprehensive Attention Test) is a web-based test to comprehensively assess attention in children, adolescents, and adults.
It examines 5 different types of attention in 6 different tests: simple attention, selective attention, sustained attention, divided attention, and working memory. This allows you to assess whether you have attention level issues in each area.
Happymind Comprehensive attention Test helps objective assessment of attention
3
Validated for reliability and accuracy through standardized studies with children and adolescents in Korea
Results can be interpreted in conjunction with intelligence tests, attention tests, and other academic achievement tests to increase the reliability of learning disorder diagnosis
CLT-R: 9 Tests for Dyslexia
Word Reading / Paragraph Reading / Sound Blending
/ Nonword Repetition / Rapid Automatized Naming
/ Letter-Sound Matching
CLT-M: 7 Tests for Dyscalculia
Computation / Magnitude Comparing / Distance Comparing / Enumeration / Estimation / Working Memory / Digit Span
CLT
Happymind’s CLT (Comprehensive Learning Test) is a web-based test for the early screening, diagnosis and measurement of improvement in children and adolescents at risk for dyslexia and dyscalculia.
It consists of small tests in reading and calculation.
Comprehensive Learning Test for early detection of dyslexia and dyscalculia in children and adolescents
4
Introducing Global Leaders of Emocog
The three founders of Emocog are all medical professionals. Our employees are also from leading companies around the world, united by a global mindset and a strong passion for what we do.
In addition, we are partnering with our German team, with backgrounds and experience in various fields such as data technology and medical engineering, to enter the European and global markets.
Leadership
Clinical & Regulatory
Medical Advisor
Yongjoon Yoo,
MD
Seoul National University, College of Medicine (MD)
Psychiatrist
Happymind CEO
Sunghee Kang,
MA
New York University, Masters of Applied Psychology
Head of Happymind Lab
EVP & CMO
June Sik Mune, MD, PhD
Seoul National University, College of Medicine
Soonchunhyang University College of Medicine, PhD
Former LG Chem, Head of Clinical & Regulatory Affairs Center
Scientific Board & Founder
Jung Hae Youn,
PhD
Paris 7, PhD
CEO of Cha Psychological Counselling Center
Professor at Cha University
College of Medicine (Psychology)
Co-CEO & Founder
Yoo Hun Noh,
PhD
Chung-Ang University, College of Medicine, PhD
Former Professor at Chung-Ang University College of Medicine (Human Anatomy)
Consulting Member at KISTEP
Co-CEO & Founder
Jun Young Lee,
MD, PhD
Seoul National University, College of Medicine, PhD (Psychiatry)
Professor at Seoul National University College of Medicine (Psychiatry)
Korean Elderly Psychiatric Association
Director of Society for Cognitive Intervention
DTx Development
Product Owner
Hairin Kim,
PhD
Seoul National University, PhD (Clinical Psychology)
Clinical Psychologist certified by Korean Clinical Psychology Association
COO Europe
Lukas Stenzel,
PhD
University of Halle-Wittenberg, PhD (Psychology)
Former CEO, Mindance
CTO Europe
Maximilian Bügler,
PhD
Technical University Munich, PhD
Former CTO, Altoida Inc.
CTO Korea
Joonsang Jo
Seoul National University, Bachelor’s (Computer Science and Engineering)
Former Software Engineer, SAP
Global Business
COO Korea
Seul Gyu Park,
MSc
SciencePo Paris, Master’s (Business Management)
M&A, Corporate Strategy
Former Management Consulting firm (Europe)
CEO Europe
Hannes Funk,
MSc
SciencePo Paris, Master’s (Economics/Business Management)
M&A, Finance Strategy
Finance at Siemens Germany / Switzerland
CBO
Brian Lim
Korea University, Bachelor’s (Business Management)
Merck-Harvard Executive Business School
Former CBO, Merck (MSD)
History, Investment, and News
During the past year, Emocog raised funds and established partnerships with renowned companies worldwide.
Company
Pre-Series A Funding Round
-
Naver-Stonebridge
-
Kakao-Shinhan Bank
-
SV Investment
-
Green Cross Holdings
-
NSR Report By US FDA complete
-
Cogthera certified for clinical trials in Korea
-
Samsung Finance Open Collaboration: Excellence Prize Winner
-
IFA 2022, 5-HT Germany Startup Pitch Winner
-
Cogthera US FDA Pre-submission
-
Establishment of Cogthera GmbH in Germany
-
Participated in CES 2022
-
Development of Cothera 1.0
-
GMP certification for Cogthera clinical trials
2022
Seed Funding Round
-
Naver-Stonebridge
-
Kakao-Shinhan Bank
-
Naver D2SF
-
Joined the Digital Therapeutics Alliance (DTA) membership
-
Signed MOU with Eisai Korea
-
Secured 23 related patents (9 registered, 14 filed)
-
Selected for Early Startup Package Project by Ministry of SMEs and Startups
-
Establishment and certification of in-house research institute
-
Establishment of Emocog, Inc.
2021
-
Development of MemoryPick (기억콕콕)
-
Cogthera: Designated as the 35th Innovative Medical Device (Cutting Edge Technologies Sector)
-
Initiated Pivotal Trials for Cogthera in Korea
-
Cogthera GmbH, 5-HT Digital Hub “Healthcare for Pharma” Prize
-
Acquired Happymind (Learning Disorder Solution Company)
2023
Partners
News
Come and make a new history with Emocog
Hiring All Positions Now
Why Emocog
We create technology that helps sustain brain health
Dementia affects about 10% of the senior population and progresses over a decade. The stage of memory decline before dementia is called Mild Cognitive Impairment (MCI) and progresses overhalf a decade. The prevalence rate is about 25%.
Emocog develops solutions for each stage of dementia, including Cogthera, a cognitive improving digital therapeutics for MCI.
Research
Technology based on world-class scientific results
The results of 20 years of research was published in 5 leading *SCI-indexed journals on brain disease.
*Science Citation Index (SCI): renowned journals carefully selected based on strict criteria among science and technology journals
Come and make
a new history
with Emocog
Hiring All Position Now
2
Software as a Medical Device to improve Mild Cognitive Impairment
Cogthera constantly monitors patients’ cognitive functions and provides personalized cognitive training to strengthen the neural networks and increase the *cognitive reserve.
It was designated as an Innovative Medical Device by MFDS and became the first cognitive intervention treatment software for MCI to be designated as an Innovative Medical Device in Korea.
Cogthera
Conversation-based interface using vocal cues, made for the convenience of patients with early cognitive decline.
After accurate assessments of the patient’s cognitive ability, training contents are automatically generated via AI technology, providing personalized training with difficulty adjustments.
Accessible anytime and anywhere, free from restraints of professional presence, location, and time.
In addition to clinical trials in Korea, Cogthera is simultaneously pursuing German DiGA (Digital treatment and medical applications). DiGA is a fast-track system by German regulatory, BfArM, with an advantage of fast market entry and high reimbursement rate.
DiGA Fast Track
Company
History, Investment, and News
During the past year, Emocog raised funds and established partnerships with renowned companies worldwide.
2023
-
Development of MemoryPick (기억콕콕)
-
Cogthera: Designated as the 35th Innovative Medical Device (Cutting Edge Technologies Sector)
-
Initiated Pivotal Trials for Cogthera in Korea
-
Cogthera GmbH, 5-HT Digital Hub “Healthcare for Pharma” Prize
-
Acquired Happymind (Learning Disorder Solution Company)
2022
-
NSR Report By US FDA complete
-
Cogthera certified for clinical trials in Korea
-
Samsung Finance Open Collaboration: Excellence Prize Winner
-
IFA 2022, 5-HT Germany Startup Pitch Winner
-
Cogthera US FDA Pre-submission
-
Establishment of Cogthera GmbH in Germany
-
Participated in CES 2022
-
Development of Cothera 1.0
-
GMP certification for Cogthera clinical trials
Pre-Series A Funding Round
-
Naver-Stonebridge
-
Kakao-Shinhan Bank
-
SV Investment
-
Green Cross Holdings
2021
-
Joined the Digital Therapeutics Alliance (DTA) membership
-
Signed MOU with Eisai Korea
-
Secured 23 related patents (9 registered, 14 filed)
-
Selected for Early Startup Package Project by Ministry of SMEs and Startups
-
Establishment and certification of in-house research institute
-
Establishment of Emocog, Inc.
Seed Funding Round
-
Naver-Stonebridge
-
Kakao-Shinhan Bank
-
Naver D2SF
4
Comprehensive Learning Test for early detection of dyslexia and dyscalculia in children and adolescents
Happymind’s CLT (Comprehensive Learning Test) is a web-based test for the early screening, diagnosis and measurement of improvement in children and adolescents at risk for dyslexia and dyscalculia.
It consists of small tests in reading and calculation.
CLT
Validated for reliability and accuracy through standardized studies with children and adolescents in Korea
The only attention test certified by the Korean Academy of Child and Adolescent Psychiatry
CLT-R: 9 Tests for Dyslexia
Word Reading / Paragraph Reading / Sound
Blending / Nonword Repetition / Rapid
Automatized Naming / Letter-Sound
Matching
CLT-M: 7 Tests for Dyscalculia
Computation / Magnitude Comparing
/ Distance Comparing / Enumeration
/ Estimation / Working Memory / Digit Span
Leadership
Introducing Global Leaders of Emocog
The three founders of Emocog are all medical professionals. Our employees are also from leading companies around the world, united by a global mindset and a strong passion for what we do.
In addition, we are partnering with our German team, with backgrounds and experience in various fields such as data technology and medical engineering, to enter the European and global markets.
Clinical & Regulatory
DTx Development
Global Business
3
Happymind Comprehensive attention Test helps objective assessment of attention
Happymind’s CAT (Comprehensive Attention Test) is a web-based test to comprehensively assess attention in children, adolescents, and adults.
It examines 5 different types of attention in 6 different tests: simple attention, selective attention, sustained attention, divided attention, and working memory. This allows you to assess whether you have attention level issues in each area.
It examines 5 different types of attention in 6 different tests: simple attention, selective attention, sustained attention, divided attention, and working memory. This allows you to assess whether you have attention level issues in each area.
CAT
Completed a standardized study of 4-49 years olds, providing more objective results
The only attention test certified by the Korean Academy of Child and Adolescent Psychiatry
1
Mobile cognitive assessment service to help screen for dementia risk
MemoryPick is a digital screening tool that helps users detect early signs of cognitive decline. It evaluates memory and executive function, which are the first cognitive areas to decline due to dementia, as well as subjective cognitive decline and depression.
At the end of the test, it shows an instant results report representing the user’s brain health. Based on the results, it recommends memory strategies to help daily life and lifestyle habits to keep the brain healthy.
MemoryPick
It is a responsive web-based online test that can be performed on various devices and operating systems through a QR or a URL.
The test takes only about 5 minutes, providing comfortable and easy-to-use content based on simple words and shapes.
Improve the accuracy of the results through large-scale compliance data by accounting for differences in cognitive function based on age, education, gender, etc.
Solution 1
Emocog’s Digital Dementia Solutions
Emocog builds an ecosystem to care for the entire journey from screening, diagnosis and treatment of dementia.
To overcome the physical constraints of not being able to care for every patient every day, we propose innovative solutions utilizing digital technology.
*Digital treatments and medical applications(DiGA) are virtual medical products that are available as apps for mobile devices or as browser applications. Cogthera DE can quickly enter the market and receive very high insurance rates through these processes.
MemoryPick
Mobile Cognitive Assessment Service to Screen for Dementia Risk
LAUNCH
Cogthera KR
Digital Therapeutics for MCI
CLINICAL
EVALUATION
Cogthera DE
German-optimized Digital Therapeutics for MCI (DiGA* fast track process in Germany)
CLINICAL
EVALUATION
PDT
Parkinson’s Disease Diagnostic Assistant Software
PROTOTYPE
& TEST
AlzVoice
Memory and Attention Assessment Service based on Verbal Conversation
PROTOTYPE
& TEST
Solution 2
Digital Solutions for Learning Disorder
With Happymind, the developer of CAT, which has a high market share in Korea, we are rapidly growing by sharing development technology, know-how, and networks accumulated over the years.
Happymind evaluates problems related to learning disorders such as attention deficit, poor reading skills and poor math skills, and provides solutions to them.
CAT
Comprehensive Attention Test for children and adults
LAUNCH
sCAT
Short version of CAT for institutions
LAUNCH
CLT
Comprehensive Learning Test for early screening of dyslexia and dyscalculia in children and adolescents
LAUNCH
NeuLearn
Application using neuroscience-based learning techniques to help memorize English words
DATA COLLECTION
& ANALYSIS
Dyscalculia Treatment Program
Program to treat those with mathematical and calculational difficulties
CONCEPT
DEVELOPMENT
Partners
News
